Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

India’s API Build-Up Plan To Bridle The Dragon

This article was originally published in PharmAsia News

Executive Summary

An Indian expert committee has recommended a raft of measures to revive and promote the production of active pharmaceutical ingredients (APIs) in the country, including the "judicious and liberal" use of anti-dumping duties and safeguards, with an eye on the country's huge reliance on Chinese imports.

You may also be interested in...



Indian Pharma Monitoring Coronavirus Fallout On Production

With several Chinese manufacturing facilities shut at least till 10 February, Indian pharma companies are keeping a close watch on the evolving coronavirus situation. API inventory can last for a while, but if intermediates supplies don’t resume soon the fallout could be grim.

China API Alert, Indian Firms Brace For More Pain

Prices of active pharmaceutical ingredients and intermediates from China have gone up significantly, piling pressure on Indian and Western companies that rely on it for supplies. Some firms are scrambling to draw up a plan B to secure supplies as the Asian giant weeds out polluting units and ups compliance.

India’s Draft Plan To End API Reliance On China ‘Needs Work’

India has come up with a draft policy proposal to end the dependence of the country’s generic drug industry on Chinese bulk drug imports but it’s sketchy on measures, at least so far, to promote domestic production and “needs work.”

Related Content

Topics

UsernamePublicRestriction

Register

LL1134409

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel